Payment overview · 2025
General Payments
$194.48
9 reported records · 6 companies
Healthcare provider profile · identity verified
Thomas K Gaide, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PUEBLO, CO · NPI 1447301791
Verified facts
What the public records show
CMS Open Payments records show Thomas K Gaide, MD received $194.48 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.55 | 25.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.15 | 22.2% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.07 | 20.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.69 | 13.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.69 | 9.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.33 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $194.48 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $39.07 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 78 |
| Lisinopril | Lisinopril | 312 | 80 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 223 | 53 |
| Omeprazole | Omeprazole | 199 | 53 |
| Simvastatin | Simvastatin | 154 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 148 | 46 |
| Losartan Potassium | Losartan Potassium | 137 | 35 |
| Potassium Chloride | Potassium Chloride | 124 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 37 |
| Prednisone | Prednisone | 117 | 63 |
| Tramadol Hcl | Tramadol Hcl | 110 | 24 |
| Gabapentin | Gabapentin | 109 | 22 |
| Metformin Hcl | Metformin Hcl | 99 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 23 |
| Furosemide | Furosemide | 97 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 20 |
| Lorazepam | Lorazepam | 74 | 22 |
| Azithromycin | Azithromycin | 73 | 50 |
| Sertraline Hcl | Sertraline Hcl | 70 | 15 |
| Donepezil Hcl | Donepezil Hcl | 66 | 12 |
| Synthroid | Levothyroxine Sodium | 63 | 18 |
| Eliquis | Apixaban | 61 | 19 |
| Glipizide | Glipizide | 58 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 17 |
| Allopurinol | Allopurinol | 55 | 15 |
| Trazodone Hcl | Trazodone Hcl | 53 | 11 |
| Alprazolam | Alprazolam | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 48 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 11 |
| Bumetanide | Bumetanide | 46 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 11 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 22 |
| Atenolol | Atenolol | 43 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 43 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 11 |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 34 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 22 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 28 | 27 |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Carvedilol | Carvedilol | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 13 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 13 |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paricalcitol | Paricalcitol | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $194.48 · 9 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AREXVY, COMIRNATY, OTEZLA, Ozempic, PREVNAR 20, REPATHA, SHINGRIX, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error